BIOQUAL, Inc.
BIOQ
$35.20
-$2.31-6.16%
OTC PK
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Revenue | -29.86% | -3.65% | -16.27% | -1.10% | -8.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -29.86% | -3.65% | -16.27% | -1.10% | -8.54% |
| Cost of Revenue | -13.87% | -13.34% | -20.77% | -27.07% | -13.05% |
| Gross Profit | -95.97% | 985.39% | 100.23% | 46.98% | 16.42% |
| SG&A Expenses | -13.38% | -16.99% | -11.12% | 1.15% | -25.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.81% | -13.81% | -19.59% | -14.52% | -14.85% |
| Operating Income | -205.75% | 77.45% | 54.15% | 94.06% | 384.83% |
| Income Before Tax | -180.38% | 88.67% | 63.15% | 101.45% | 240.53% |
| Income Tax Expenses | -180.35% | 88.66% | 63.12% | 119.32% | 240.98% |
| Earnings from Continuing Operations | -180.40% | 88.67% | 63.16% | 91.78% | 240.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -180.40% | 88.67% | 63.16% | 91.78% | 240.36% |
| EBIT | -205.75% | 77.45% | 54.15% | 94.06% | 384.83% |
| EBITDA | -139.16% | 112.75% | 109.28% | 133.02% | 100.48% |
| EPS Basic | -180.40% | 88.67% | 63.15% | 91.78% | 240.33% |
| Normalized Basic EPS | -180.39% | 88.67% | 63.14% | 101.45% | 240.53% |
| EPS Diluted | -180.40% | 88.71% | 63.16% | 91.67% | 240.33% |
| Normalized Diluted EPS | -180.39% | 88.67% | 63.14% | 101.45% | 240.53% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | 0.00% | -- |
| Payout Ratio | -- | -- | -- | -- | -- |